Neuroscience is undergoing its most significant therapeutic breakthrough in a generation. The approval of the first disease-modifying Alzheimer’s treatments — Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi — has opened a category that failed to produce a single approved mechanism-based therapy for more than two decades. AbbVie’s Vraylar at $3.6 billion, J&J’s Spravato, and BMS’s Cobenfy are reshaping the CNS competitive landscape simultaneously.
Topics Covered
• Alzheimer’s Disease
• Depression and Mood Disorders
• Schizophrenia and Psychotic Disorders
• Parkinson’s Disease
• Multiple Sclerosis
• Pain and Neuroinflammation
• Rare CNS Disease
Table of Contents
1. Executive Summary
2. Market Overview
3. Alzheimer’s Disease
4. Depression and Mood Disorders
5. Schizophrenia and Psychotic Disorders
6. Parkinson’s Disease
7. Multiple Sclerosis
8. Pain and Neuroinflammation
9. Rare CNS Disease
10. Competitive Landscape
11. Regional Market Analysis
12. Strategic Conclusions and Recommendations
13. Appendix
List of Tables
Table 1. Market Overview and Leading Products 2025
Table 2. Competitive Landscape by Sub-Segment 2025
Table 3-8. Topic-Specific Analysis Tables
Table 3. Leading Companies — Portfolio and Pipeline Assessment 2025
Table 4. M&A and Licensing Activity 2023-2025
Table 5. Regional Market Analysis
Table 6. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
